Lessons from a molecular tumor board in hematologic malignancies​

Next-generation sequencing (NGS) has transformed the diagnosis and management of haematologic malignancies, providing increasingly detailed insights into the molecular drivers of disease. However, many workflows continue to rely on single time point genomic assessments, limiting opportunities to leverage sequencing data throughout the patient journey.​

In this webcast, Dr Todd Knepper of Moffitt Cancer Center will share lessons from a molecular tumour board and discuss how genomic information can support decision-making beyond initial diagnosis. Drawing on clinical experience and real-world examples, he will explore the role of NGS for risk assessment, monitoring clonal evolution, post-transplant surveillance and the interpretation of complex molecular findings.​

He will also examine the challenges posed by clonal haematopoiesis of indeterminate potential (CHIP) and the importance of multidisciplinary approaches to genomic interpretation. Attendees will gain insight into emerging strategies for identifying and monitoring high-risk cases, and how expanded NGS applications might help to integrate precision oncology more effectively into routine haematology practice.​

Learn:​

• How molecular tumour boards translate complex genomic findings in actionable insights​
• What limits the wider use of NGS in blood cancer patient journeys​
• Which emerging strategies could help to bring precision oncology into routine haematology practice​

Speakers:​

Todd Knepper​
Associate Member, Precision Oncology​
Department of Pathology, Moffitt Cancer Center​

Moderator:

Nikki Forrester​
Freelance Science​ Writer and Editor​